Modulation of defensive behavior by Transient Receptor Potential Vanilloid Type-1 (TRPV1) channels. 2014

D C Aguiar, and F A Moreira, and A L Terzian, and M V Fogaça, and S F Lisboa, and C T Wotjak, and F S Guimaraes
Department of Pharmacology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Av. Antônio Carlos 6627, Belo Horizonte, MG, 31270-901, Brazil.

The Transient Receptor Potential Vanilloid Type-1 (TRPV1) was first characterized in primary afferent fibers as a receptor for capsaicin (the pungent ingredient of chili peppers). Later on, this cation-permeable ion channel was also described in the central nervous system, where its main putative endogenous ligand is N-arachidonoyl ethanolamide (an endocannabinoid, also known as anandamide). Recent results employing genetic, pharmacological and histochemical techniques indicate that TRPV1 tonically modulate anxiety, fear and panic responses in brain regions related to defensive responses, such as the dorsal periaqueductal gray, the hippocampus and the medial prefrontal cortex. Genetic deletion or antagonism of this ion channel induces anxiolytic-like effects in several animal models. The main mechanism responsible for TRPV1-mediated effects on anxiety seems to involve facilitation of glutamatergic neurotransmission. In addition, there is evidence for interactions with other neurotransmitter systems, such as nitric oxide and endocannabinoids.

UI MeSH Term Description Entries
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D003674 Defense Mechanisms Unconscious process used by an individual or a group of individuals in order to cope with impulses, feelings or ideas which are not acceptable at their conscious level; various types include reaction formation, projection and self reversal. Mechanisms, Defense
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001007 Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS. Angst,Anxiousness,Hypervigilance,Nervousness,Social Anxiety,Anxieties, Social,Anxiety, Social,Social Anxieties
D050916 TRPV Cation Channels A subgroup of TRP cation channels named after the vanilloid receptor. They are very sensitive to TEMPERATURE; hot spicy food, and CAPSAICIN. They contain a TRP domain (a five-turn amphipathic helix with an invariant TRYPTOPHAN) and ANKYRIN repeats. Selectivity for CALCIUM over SODIUM ranges from 3 to 100 fold. Capsaicin Receptor,Vanilloid Receptor,Capsaicin Receptors,Vanilloid Receptors,Cation Channels, TRPV,Channels, TRPV Cation,Receptor, Capsaicin,Receptor, Vanilloid,Receptors, Capsaicin,Receptors, Vanilloid

Related Publications

D C Aguiar, and F A Moreira, and A L Terzian, and M V Fogaça, and S F Lisboa, and C T Wotjak, and F S Guimaraes
August 2007, Biochimica et biophysica acta,
D C Aguiar, and F A Moreira, and A L Terzian, and M V Fogaça, and S F Lisboa, and C T Wotjak, and F S Guimaraes
January 2021, European journal of pain (London, England),
D C Aguiar, and F A Moreira, and A L Terzian, and M V Fogaça, and S F Lisboa, and C T Wotjak, and F S Guimaraes
March 2016, The Journal of physiology,
D C Aguiar, and F A Moreira, and A L Terzian, and M V Fogaça, and S F Lisboa, and C T Wotjak, and F S Guimaraes
September 2005, The Journal of physiology,
D C Aguiar, and F A Moreira, and A L Terzian, and M V Fogaça, and S F Lisboa, and C T Wotjak, and F S Guimaraes
January 2011, Current pharmaceutical biotechnology,
D C Aguiar, and F A Moreira, and A L Terzian, and M V Fogaça, and S F Lisboa, and C T Wotjak, and F S Guimaraes
June 2015, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society,
D C Aguiar, and F A Moreira, and A L Terzian, and M V Fogaça, and S F Lisboa, and C T Wotjak, and F S Guimaraes
February 2014, Molecular pharmacology,
D C Aguiar, and F A Moreira, and A L Terzian, and M V Fogaça, and S F Lisboa, and C T Wotjak, and F S Guimaraes
April 2024, Brain research bulletin,
D C Aguiar, and F A Moreira, and A L Terzian, and M V Fogaça, and S F Lisboa, and C T Wotjak, and F S Guimaraes
October 2008, Molecular pain,
D C Aguiar, and F A Moreira, and A L Terzian, and M V Fogaça, and S F Lisboa, and C T Wotjak, and F S Guimaraes
October 2010, Biochemical and biophysical research communications,
Copied contents to your clipboard!